294 related articles for article (PubMed ID: 34051805)
1. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Rong QX; Wang F; Guo ZX; Hu Y; An SN; Luo M; Zhang H; Wu SC; Huang HQ; Fu LW
Mol Cancer; 2021 May; 20(1):80. PubMed ID: 34051805
[TBL] [Abstract][Full Text] [Related]
2. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
3. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
5. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
[TBL] [Abstract][Full Text] [Related]
7. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
8. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
[TBL] [Abstract][Full Text] [Related]
11. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer.
Yonemitsu K; Pan C; Fujiwara Y; Miyasato Y; Shiota T; Yano H; Hosaka S; Tamada K; Yamamoto Y; Komohara Y
Sci Rep; 2022 Jul; 12(1):12007. PubMed ID: 35835809
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL; Nairismägi ML; Laurensia Y; Lim JQ; Tan J; Li ZM; Pang WL; Kizhakeyil A; Wijaya GC; Huang DC; Nagarajan S; Chia BK; Cheah D; Liu YH; Zhang F; Rao HL; Tang T; Wong EK; Bei JX; Iqbal J; Grigoropoulos NF; Ng SB; Chng WJ; Teh BT; Tan SY; Verma NK; Fan H; Lim ST; Ong CK
Blood; 2018 Sep; 132(11):1146-1158. PubMed ID: 30054295
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
17. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
[TBL] [Abstract][Full Text] [Related]
18. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
19. The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma.
Gao LM; Zhang YH; Shi X; Liu Y; Wang J; Zhang WY; Liu WP
Front Oncol; 2022; 12():821918. PubMed ID: 35619907
[TBL] [Abstract][Full Text] [Related]
20. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
Kim SJ; Lim JQ; Laurensia Y; Cho J; Yoon SE; Lee JY; Ryu KJ; Ko YH; Koh Y; Cho D; Lim ST; Enemark MB; D'Amore F; Bjerre M; Ong CK; Kim WS
Blood; 2020 Dec; 136(24):2754-2763. PubMed ID: 32766875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
